Keyphrases
Overall Survival
100%
Multi-institutional
100%
Molecular Alterations
100%
Astrocytoma
100%
Isocitrate Dehydrogenase 1 (IDH1)
100%
Hazard Ratio
71%
BRCA2
42%
Central Nervous System
42%
World Health Organization Grade
42%
Tumor mutation Burden
28%
Tumor Protein p53 (TP53)
14%
Prognostic Value
14%
Histological Grade
14%
Multivariable
14%
Survival Data
14%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
14%
Univariate Analysis
14%
Kaplan-Meier Method
14%
Tuberous Sclerosis Complex
14%
ARID1A
14%
BRCA2 mutation
14%
Cox Proportional Hazards Regression Model
14%
Risk Stratification
14%
Frequent mutation
14%
Prognostic Implications
14%
IDH2 mutation
14%
Diffuse Astrocytoma
14%
Mutation Mutation
14%
CREB1
14%
Pharmacology, Toxicology and Pharmaceutical Science
Retrospective Study
100%
Overall Survival
100%
Astrocytoma
100%
Isocitrate Dehydrogenase
100%
Neoplasm
28%
Diseases
14%
Cyclin Dependent Kinase Inhibitor 2A
14%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Retrospective Study
100%
Isocitrate Dehydrogenase
100%
BRCA2
57%
ARID1A
14%
TSC2
14%
Alpha Thalassemia/Mental Retardation X-Linked
14%
IDH1
14%
IDH2
14%
Cyclin Dependent Kinase Inhibitor 2A
14%
Neuroscience
Astrocytoma
100%
Isocitrate Dehydrogenase
100%
Central Nervous System
60%
TP53
20%
IDH2
20%
ARID1A
20%